The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12

被引：0

作者：

Dignass, A. ^{[1
]}

Rubin, D. ^{[2
]}

Bressler, B. ^{[3
]}

Huang, K. H. ^{[4
]}

Shipitofsky, N. ^{[4
]}

Germinaro, M. ^{[4
]}

Zhang, H. ^{[4
]}

Johanns, J. ^{[4
]}

Feagan, B. ^{[5
]}

Sandborn, W. ^{[6
]}

Sands, B. ^{[7
]}

Hisamatsu, T. ^{[8
]}

Lichtenstein, G. ^{[9
]}

Panes, J. ^{[10
]}

Allegretti, J. ^{[11
]}

机构：

[1] Agaples Markus Hosp, Dept Med, Frankfurt, Germany

[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[3] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada

[4] Janssen Res & Dev LLC, Immunol, Spring House, PA USA

[5] Western Univ, Robarts Clin Trials, London, ON, Canada

[6] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA USA

[7] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA

[8] Kyorin Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan

[9] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA

[10] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

[11] Brigham & Womens Hosp, Crohns & Colitis Ctr, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA

来源：

JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OP23

引用

页码：I025 / I026

页数：3

共 50 条

[31] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Louis, Edouard
Panaccione, Remo
Parkes, Gareth
Pevrin-Biroulet, Laurent
Ferrante, Marc
Takeuchi, Ken
Siegmund, Britta
Levine, Phillip
Kalabic, Jasmina
Neimark, Ezequiel
Wallace, Kori
Chen, Su
Duan, W. Rachel
Armuzzi, Alessandro
Biedermann, Luc
Loftus, Edward
Melmed, Gil
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S3 - S3
[32] Corticosteroid Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44
Bressler, Brian
Allegretti, Jessica R.
Rubin, David T.
Shipitofsky, Nicole
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Armuzzi, Alessandro
Fishman, Sigal
Wang, Yufang
Panes, Julian
Lichtenstein, Gary R.
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1002 - S1002
[33] Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study
Panes, Julian
Dignass, Axel
Hisamatsu, Tadakazu
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Sridhar, Sunandini
Branigan, Patrick
Wilson, Rebbecca
Zhang, Hongyan
Magro, Fernando
Jairath, Vipul
Feagan, Brian G.
Lichtenstein, Gary R.
Rubin, David T.
Sands, Bruce E.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1041 - S1041
[34] Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
Danese, S.
Vermeire, S.
Zhou, W.
Pangan, A.
Siffledeen, J.
Hebuterne, X.
Nakase, H.
Higgins, P.
Chen, M. H.
Sanchez-Gonzalez, Y.
Huang, B.
Xie, W.
Liu, J.
Weinreich, M.
Pannaccione, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S022 - S024
[35] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
Danese, Silvio
Vermeire, Severine
Zhou, Wen
Pangan, Aileen
Siffledeen, Jesse
Hebuterne, Xavier
Nakase, Hiroshi
Chen, Minhu
Higgins, Peter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S312 - S313
[36] Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
Vermeire, Severine
Danese, Silvio
Zhou, Wen
Pangan, Aileen
Greenbloom, Susan
D'Haens, Geert
Panes, Julian
Juillerat, Pascal
Lindsay, James
Loftus, Edward V.
Sandborn, William
Reinisch, Walter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S357
[37] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
Andrews, J. M.
D'Haens, G.
Kobayashi, T.
Morris, N.
Lissoos, T.
Hoover, A.
Li, X.
Arora, V.
Milch, C.
Sandborn, W. J.
Sands, B. E.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
[38] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
D'Haens, G.
Kobayashi, T.
Morris, N.
Lissoos, T.
Hoover, A.
Li, X.
Arora, V.
Milch, C.
Sandborn, W. J.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
[39] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
Vermeire, S.
Danese, S.
Zhou, W.
Pangan, A.
Greenbloom, S.
D'Haens, G.
Panes, J.
Juillerat, P.
Lindsay, J. O.
Loftus, E. V., Jr.
Sandborn, W. J.
Reinisch, W.
Gonzalez, Y. Sanchez
Huang, B.
Xie, W.
Liu, J.
Weinreich, M. A.
Panaccione, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
[40] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
D'Haens, Geert
Kobayashi, Taku
Morris, Nathan
Lissoos, Trevor
Hoover, Amy
Li, Xingyuan
Arora, Vipin
Milch, Catherine
Sandborn, William J.
Sands, Bruce E.
GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214

← 1 2 3 4 5 →